Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Completed
Phase 2

Conditions

HIV Infections

Treatments

Drug: Atazanavir
Drug: Didanosine
Drug: Nelfinavir mesylate
Drug: Stavudine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00002240
AI424-007
302A

Details and patient eligibility

About

The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine). The effectiveness of BMS-232632 against HIV infection will be compared to that of nelfinavir, a protease inhibitor that is already commonly prescribed.

Full description

Patients are randomized to receive one of two drug regimens: BMS-232632, ddI, and d4T or NFV, ddI, and d4T. Three different doses of BMS-232632 are used in this study. Randomization is stratified for HIV RNA level (less than 30,000 copies/ml versus 30,000 or greater copies/ml). Patients remain on their drug regimen for 48 weeks.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients may be eligible for this study if they:

  • Are HIV-positive.
  • Have an HIV blood level between 2,000 and 200,000 copies/ml.
  • Have a CD4 cell count of at least 100 cells/mm3.
  • Are 18 years of age or older.
  • Are available for follow-up for at least 48 weeks.
  • Agree to use a barrier method of birth control (such as condoms) during the study.

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have ever received anti-HIV (antiretroviral) treatment.
  • Have an HIV-related opportunistic infection or condition at the time of study entry.
  • Have primary HIV infection, meaning they have recently been infected.
  • Have had severe diarrhea within the 30 days before study entry.
  • Have hemophilia.
  • Have a history of pancreatitis, hepatitis, or a peripheral neuropathy.
  • Are unable to tolerate oral medication.
  • Are pregnant or breast-feeding.
  • Abuse alcohol or drugs.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems